DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events

Phase 4

Completed

Conditions: Thalassemia

First Posted Date: 2006-06-29

Last Posted Date: 2012-05-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT00346242

Locations: 🇬🇷
Novartis Investigative Site, Athens, Greece

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Phase 3

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: imatinib mesilate
Drug: interferon-alpha (INF-a)
Drug: cytarabine (ARA-C)

First Posted Date: 2006-06-06

Last Posted Date: 2013-10-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1106

Registration Number: NCT00333840

Locations: 🇬🇧
Novartis Investigative Site, Plymouth, United Kingdom

Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer

Phase 4

Completed

Conditions: Breast Cancer
Bone Metastasis
Prostate Cancer

Interventions: Drug: Zoledronic Acid

First Posted Date: 2006-06-06

Last Posted Date: 2017-02-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 411

Registration Number: NCT00334139

Locations: 🇩🇪
Novartis Investigative Site, Ulm, Germany

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Phase 2

Completed

Conditions: Peritoneal Neoplasms
Intestinal Obstruction
Carcinomatosis

Interventions: Drug: Octreotide LAR
Drug: Placebo
Drug: Octreotide (Immediate release)
Drug: methylprednisolone

First Posted Date: 2006-06-02

Last Posted Date: 2011-09-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT00332696

Locations: 🇫🇷
Novartis Investigative Site, Creteil, France

Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Letrozole

First Posted Date: 2006-06-02

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 655

Registration Number: NCT00332852

Locations: 🇩🇪
Novartis Investigative Site, Wolfsburg, Germany
🇩🇪
Schorndorf, Konstanz, Germany
🇩🇪
Novartis Investigative site, Celle, Germany

A Study of Letrozole in the Treatment of Endometrial Cancer

Phase 2

Completed

Conditions: Recurrent and Metastatic Endometrial Cancer

First Posted Date: 2006-06-02

Last Posted Date: 2012-04-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT00333086

Locations: 🇩🇪
Novartis Investigative Site, Heidelberg, Germany

Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

Phase 2

Completed

Conditions: Thymoma

Interventions: Drug: Octreotide

First Posted Date: 2006-06-02

Last Posted Date: 2017-03-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT00332969

Locations: 🇩🇪
Novartis Investigative Site, Regensburg, Germany

Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

Phase 4

Terminated

Conditions: Renal Transplantation

Interventions: Drug: Cyclosporin A (CsA)
Drug: Everolimus
Drug: Tacrolimus
Drug: Corticosteroids
Drug: Enteric Coated - Mycophenolate Sodium (EC-MPS)

First Posted Date: 2006-06-02

Last Posted Date: 2014-08-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 93

Registration Number: NCT00332839

Locations: 🇩🇪
Novartis Investigative Site, Muenster, Germany

A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

Phase 4

Terminated

Conditions: Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women

Interventions: Drug: Placebo
Drug: Zoledronic Acid

First Posted Date: 2006-06-02

Last Posted Date: 2014-11-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 11

Registration Number: NCT00333229

Locations: 🇩🇪
Novartis Investigative Site, Marburg, Germany

A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients

Phase 4

Completed

Conditions: Liver Transplantation

Interventions: Drug: Cyclosporine (Sandimmun® i.v.)
Drug: Cyclosporine (Sandimmun® Optoral)

First Posted Date: 2006-06-01

Last Posted Date: 2011-03-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT00332462

Locations: 🇩🇪
Novartis Investigational Site, Various Cities, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy